The ERS/ATS Task Force (2020) made recommendations on the use of novel therapies for severe asthma, specifically biologics for type 2 high asthma, such as the anti-IL-5 mepolizumab and reslizumab, the IL-5 receptor antagonist benralizumab and dupilumab, the IL-4 and IL-13 α-chain receptor antagonist. Here, IL5 is linked to asthma.